NOX-A12

DRUG5 trials

Sponsors

TME Pharma AG

Conditions

Autologous Stem Cell TransplantationChronic Lymphocytic LeukemiaGlioblastomaHematopoietic Stem Cell TransplantationMultiple Myeloma

Phase 1

NOX-A12 First-in-human (FIH) Study

CompletedNCT00976378

TME Pharma AGAutologous Stem Cell Transplantation

Start: 2009-10-31End: 2010-05-31Updated: 2014-06-26

NOX-A12 Multiple Ascending Dose Study in Healthy Volunteers

CompletedNCT01194934

TME Pharma AGHematopoietic Stem Cell Transplantation

Start: 2010-08-31End: 2011-01-31Updated: 2014-06-26

Single-arm dose-escalation Phase 1/2 study of olaptesed pegol (NOX-A12) in combination with irradiation in inoperable or partially resected first-line glioblastoma patients with unmethylated MGMT promoter with a multiple-arm expansion group

RecruitingCTIS2024-510964-21-00

TME Pharma AGGlioblastoma

Start: 2019-09-12Target: 136Updated: 2025-11-18

Phase 2

NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL)

CompletedNCT01486797

TME Pharma AGChronic Lymphocytic Leukemia

Start: 2012-03-31End: 2017-04-30Updated: 2017-05-22

NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

CompletedNCT01521533

TME Pharma AGMultiple Myeloma

Start: 2012-03-31End: 2015-09-30Updated: 2015-10-06

Related Papers

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia

Haematologica2019-05-1685 citations

Comparison of Ibrutinib, Idelalisib and Olaptesed Pegol on the Immune Effector Function Mediated By Rituximab

Blood2014-12-06